Marfan Syndrome Clinical Trial
— LIMA IOfficial title:
Living With Marfan Syndrome I: the Psychosocial and Health-related Quality of Life Effects of the Diagnosis for Aorto-vascular Manifestations (LIMA I Study)
NCT number | NCT04776668 |
Other study ID # | 286206 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 5, 2021 |
Est. completion date | August 22, 2023 |
Verified date | April 2024 |
Source | Barts & The London NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Marfan Syndrome (MFS) is a genetic disease affecting the eyes, skeleton, heart and arteries. Despite MFS affecting multiple organ systems, cardiovascular manifestations are the most serious and life threatening. Approximately 80% of adult MFS patients will have a dilated aortic root by age 40 years with aortic aneurysm and dissection the leading causes of morbidity and mortality. Thus, MFS patients require lifelong cardiac surveillance. Living with a diagnosis of Marfan Syndrome and aorto-vascular manifestations affects patients' mental health, well-being and quality of life in ways that are not well understood. This study will address the current knowledge gaps in this area and will provide the information needed to design interventions for MFS patients with aorto-vascular problems to help improve the patients' mental health, well-being and quality of life. The study will include adult MFS patients who have been diagnosed with aorto-vascular problems. The overall aim of the study is to explore the psychosocial and health-related quality of life (HRQoL) effects of the diagnosis for aorto-vascular manifestations of MFS in 3 large UK cardiac centres. To achieve this, the researchers will ask the potential participants, after obtaining informed consent, to complete a series of accepted/validated questionnaires to measure the study participants' health-related quality of life (SF-36 and EQ5D questionnaire) and psychosocial factors such as depression (CES-D questionnaire), fatigue (Fatigue Severity Scale), stigma (Perceived Stigma Questionnaire), self-esteem (Rosenberg Self-esteem Scale), pain and illness perception (Illness Perception Questionnaire). The researcher will also conduct a one-to-one semi-structured interview with some participants to identify factors important to patients that are not captured in the questionnaires used.
Status | Completed |
Enrollment | 75 |
Est. completion date | August 22, 2023 |
Est. primary completion date | August 22, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility | Inclusion Criteria: 1. >/= 18 years old; 2. have validated diagnosis of MFS (using revised Ghent criteria); 3. diagnosed with aorto-vascular manifestations Exclusion Criteria: 1. <18years old 2. Unable or unwilling to give written informed consent. 3. Inability to understand written and/or verbal English |
Country | Name | City | State |
---|---|---|---|
United Kingdom | St Bartholomews Hospital | London |
Lead Sponsor | Collaborator |
---|---|
Barts & The London NHS Trust | Aortic Dissection Awareness UK & Ireland., Liverpool Heart and Chest Hospital NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Health-related Quality of Life (HRQoL) | HRQoL will be measured using the Short Form Health Survey 36 (SF-36). SF-36 consists of 8 sub-scales. All scales do contribute in different proportions to the scoring of the physical and mental dimensions, represented by the Physical Component Summary (PCS) and Mental Component Summary (MCS). Using an algorithm, raw scores can be converted to a transformed scale scores ranging from 0-100, with higher score indicating a better health state. | 24 hours after consent is obtained | |
Primary | Health-related Quality of Life (HRQoL) | HRQoL will be measured using EQ-5D. EQ-5D is divided into 2 components: health care description and evaluation. In the description part, summation of score ranges from 1 to 3; with 1 indicates the best health state and 3 indicates more severe or frequent problem. The evaluation part utilises a visual analogue scale to indicate the general health status with 100 indicating the best health status and 0 indicating the worst health status. | 24 hours after consent is obtained | |
Secondary | Psychosocial factor: depression | Depression will be measured using Centre for Epidemiological Studies Depression Scale (CES-D). The overall score ranges from 0 to 60, with higher scores indicating a more severe depressive symptoms. In general population, a cut-off score of 16 or above is used to identify those with significant clinical signs of depression. | 24 hours after consent is obtained | |
Secondary | Psychosocial factor: fatigue | Fatigue will be determined using Fatigue Severity Scale (FSS). The minimum possible score is 9 and maximum possible score is 63. Higher score indicates greater fatigue severity. | 24 hours after consent is obtained | |
Secondary | Psychosocial factor: stigma | Stigma will be measured using Perceived Stigma Questionnaire (PSQ). PSQ is composed of 4 sub-scales. Score on each sub-scale ranges from 1 to 6. Mean scores of >/= 2.0 on the devaluation and discrimination sub-scale indicates feeling of discriminated against or devalued. Mean scores of = 3.5 on the withdrawal and secrecy sub-scales and = 2.0 on the education sub-scale indicates the use of secrecy / withdrawal and education as coping styles, respectively. | 24 hours after consent is obtained | |
Secondary | Psychosocial factor: self esteem | Self-esteem will be measured using Rosenberg Self-esteem Scale (RSS); score ranges from 10 (min) -40 (max); higher score indicates higher self-esteem. | 24 hours after consent is obtained | |
Secondary | Psychosocial factors: pain and illness perception | Pain and Illness Perception will be determined using Illness Perception Questionnaire (IPQ). IPQ is divided into 5 components. The identity component is scored by summing the number of items identified at 'occasionally' or greater resulting to a total score ranging from 0 to 12 for the core list. The four other components are presented in mixed order and can be rated using a 5-point Likert scale ranging from 'strongly disagree' (1) to 'strongly agree (5). | 24 hours after consent is obtained |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00763893 -
Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome
|
Phase 3 | |
Recruiting |
NCT05809323 -
Marfan Syndrome Moderate Exercise Trial II
|
N/A | |
Recruiting |
NCT01949233 -
The Oxford Marfan Trial
|
Phase 2 | |
Active, not recruiting |
NCT01145612 -
Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome
|
Phase 3 | |
Completed |
NCT00723801 -
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
|
Phase 3 | |
Completed |
NCT04641325 -
Marfan Syndrome Moderate Exercise Pilot
|
N/A | |
Recruiting |
NCT06257004 -
Genome-wide Epistasis for Cardiovascular Severity in Marfan Study
|
||
Completed |
NCT01322165 -
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
|
N/A | |
Recruiting |
NCT05700175 -
Transcriptomic Study of Adult Population With Marfan Syndrome
|
||
Completed |
NCT00782327 -
Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers
|
Phase 3 | |
Not yet recruiting |
NCT05838235 -
Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Marfan Syndrome
|
N/A | |
Recruiting |
NCT02148900 -
Development of a Blood Test for Marfan Syndrome
|
N/A | |
Active, not recruiting |
NCT05980104 -
Single-Session "Empowered Relief" Class for Marfan Syndrome and Related Conditions
|
N/A | |
Recruiting |
NCT02050113 -
Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices
|
N/A | |
Completed |
NCT00001641 -
Study of Heritable Connective Tissue Disorders
|
N/A | |
Completed |
NCT01715207 -
Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol
|
Phase 3 | |
Completed |
NCT05516043 -
Safety and Performance of POLYTHESE® Vascular Prosthesis
|
||
Recruiting |
NCT04776681 -
Living With Marfans and Your Aorta: Surgical Outcomes Study
|
||
Completed |
NCT03236571 -
Cardiorespiratory and Muscular Rehabilitation of Children and Young Adults With Marfan Syndrome.
|
N/A | |
Recruiting |
NCT00683124 -
Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients
|
Phase 3 |